Single-lesion biopsy may be insufficient to choose therapy targeting resistance mutations


When metastatic tumors driven by drug-targetable genetic mutations become resistant to a targeted therapy drug, the usual practice is to biopsy a single metastatic lesion to test for new mutations… Source link